SCHEMBL23850797

SCHEMBL23850797

CC1(C)OB(c2ccc(N3CCCCC3)c(N)c2)OC1(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100B P04271 2/20 0.50
ALDH1A1 P00352 7/20 0.48
GAA P10253 6/20 0.48
KDM4E B2RXH2 5/20 0.48
HTT P42858 3/20 0.48
LMNA P02545 2/20 0.48
L3MBTL1 Q9Y468 4/20 0.44
POLB P06746 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
HSD17B10 Q99714 1/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12069326 0.99 S100B (0.47) S100BALDH1A1GAAKDM4EHTT
SCHEMBL16101225 0.87 ALDH1A1 (0.52) S100BALDH1A1GAAKDM4EHTT
SCHEMBL790920 0.84 ALDH1A3 (0.47) ALDH1A1GAAKDM4EHTTLMNA
SCHEMBL17531628 0.84 ALDH1A1 (0.47) ALDH1A1GAAKDM4EHTTLMNA
SCHEMBL13957868 0.84 ALDH1A1 (0.37) S100BALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL17531637 0.83 ALDH1A1 (0.44) ALDH1A1GAAHTTRAB9ANPC1
SCHEMBL14758377 0.82 ALDH1A1 (0.45) ALDH1A1GAAKDM4EHTTLMNA
SCHEMBL16101246 0.82 CASP6 (0.42) ALDH1A1GAAKDM4ELMNAL3MBTL1
SCHEMBL25715171 0.81 ALDH1A1 (0.44) ALDH1A1GAAHTTRAB9ANPC1
SCHEMBL13958134 0.81 DRD2 (0.38) ALDH1A1KDM4EL3MBTL1POLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 S100B 2836/4885ALDH1A1 2613/4885GAA 3530/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR S100B 2774/4885ALDH1A1 276/4885GAA 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.